Therapy of tuberculosis in mice by DNA vaccination

Nature

Volumn 400, Issue 6741, 1999, Pages 269-271

  Lowrie, Douglas B ^a   Tascon, Ricardo E ^a   Bonato, Vania L D ^b   Lima, Valeria M F ^b   Faccoli, Lucia H ^b   Stavropoulos, Evangelos ^a   Colston, M Joseph ^a   Hewinson, Robert G ^c   Moelling, Karin ^d   Silva, Celio L ^b  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c VETERINARY LABORATORIES AGENCY   (United Kingdom)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BCG VACCINE; DEXAMETHASONE; DNA VACCINE; ISONIAZID; PYRAZINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; CELLULAR IMMUNITY; CHEMOTHERAPY; DEATH; FEMALE; GROWTH INHIBITION; IMMUNE RESPONSE; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CHAPERONINS; COMBINED MODALITY THERAPY; FEMALE; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-4; ISONIAZID; MICE; MICE, INBRED BALB C; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; PLASMIDS; PYRAZINAMIDE; T-LYMPHOCYTES; TUBERCULOSIS; VACCINES, DNA;

ACTINOBACTERIA (CLASS); ANIMALIA; BACTERIA (MICROORGANISMS); MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; UNCULTURED ACTINOMYCETE;

EID: 0033566165     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/22326     Document Type: Article

References (30)

1. Kochi, A. Global challenge of tuberculosis. Lancet 44, 608-609 (1994).
2. Bloom, B. R. & Fine, P. E. M. in Tuberculosis: Pathogenesis, Protection, and Control (ed. Bloom, B. R.) 531-557 (American Society for Microbiology, Washington DC, 1994).
3. Hong Kong Chest Service & British Medical Research Council. Controlled trial of 4 three-times= weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Tubercle 63, 89-98 (1982).
4. Young, D. B. & Duncan, K. Prospects for new interventions in the treatment and prevention of mycobacterial disease. Annu. Rev. Microbiol. 49, 641-673 (1995).
5. Tascon, R. E. et al. Vaccination against tuberculosis by DNA injection. Nature Med. 2, 888-892 (1996).
6. Huygen, K. et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Med. 2, 893-898 (1996).
7. Zhu, X. J. et al. Functions and specificity of T cells following nucleic acid vaccination of mice against Mycobacterium tuberculosis infection. J. Immunol. 158, 5921-5926 (1947).
8. Bonato, V. L. D., Lima, V. M. F., Tascon, R. E., Lowrie, D. B. & Silva, C. L. Identification and characterization of protective T cells in hsp65 DNA vaccinated and Mycobacterium, tuberculosis infected mice. Infect. Immun. 66, 169-175 (1998).
9. Stenger, S. et al. An antimicrobial activity of cytolytic T cells mediated by lysin. Science 282, 121-125 (1998).
10. Altare, F. et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280, 1432-1435 (1998).
11. Donnelly, J. J., Ulmer, J. B., Shiver, J. W. & Liu, M. A. DNA vaccines. Annu. Rev. Immunol. 15, 617-648 (1997).
12. Orme, I. M., Roberts, A. D., Griffin, J. P. & Abrams, J. S. Cytokine secretion by CD4 T-lymphocytes acquired in response to Mycobacterium tuberculosis infection. J. Immunol. 15, 518-525 (1993).
13. Zhang, M. et al. T-cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect. Immun. 63, 3231-3234 (1995).
14. Krieg, A. M., LoveHoman, L., Yi, A. K. & Harty, J. T. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161, 2428-2434 (1998).
15. Lai, W. C., Pakes, S. P., Ren, K., Lu, Y. S. & Bennett, M. Therapeutic effect of DNA immunization of genetically susceptible mice infected with virulent Myco. J. Immunol. 158, 2513-2516 (1997).
16. Johnston, S. A. & Barry, M. A. Genetic to genomic vaccination. Vaccine 15, 808-809 (1997).
17. Lowrie, D. B., Silva, C. L., Colston, M. J., Ragno, S. & Tascon, R. E. Protection against tuberculosis by a plasmid DNA vaccine. Vaccine 15, 834-838 (1997).
18. Matsumoto, S. et at. Cloning and sequencing of a unique antigen MPT70 from Mycobacterium tuberculosis H37Rv and expression in BCG using E-coli Mycobacteria shuttle vector. Scand. J. Immunol. 41, 281-287 (1995).
19. Hewinson, R. G., Michell, S. L., Russell, W. P., McAdam, R. A. & Jacobs, W. R. Molecular characterization of MPT73: a seroreactive antigen of Mycobacterium tuberculosis with homology to MPT70. Scand. J. Immunol. 43, 490-499 (1996).
20. Trinchieri, G. Immunobiology of interleukin-12. Immunol. Res. 17, 269-278 (1998).
21. Flynn, J. L. et al. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol. 155, 2515-2524 (1995).
22. Cooper, A. M., Magram, J., Ferrante, J. & Orme, I. M. Interleukin 12 (IL-12) a crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis, J. Exp. Med. 186, 39-45 (1997).
23. deJong, R. et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280, 1435-1438 (1998).
24. Mitchison, D. A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66, 219-225 (1985).
25. McCune, R. M., Feldmann, F. M., Lambert, H. P. & McDermott, W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 123, 445-468 (1966).
26. Wiegeshaus, E., Balasubramanian, V. & Smith, D. W. Immunity to tuberculosis from the perspective of pathogenesis. Infect. Immun. 57, 3671-3676 (1989).
27. Smith, P. G. & Moss, A. R. in Tuberculosis: Pathogenesis, Protection, and Control (ed. Bloom, B. R.) 47-59 (American Society for Microbiology, Washington DC, 1994).
28. Tascon, R. E. et al. in Vaccine Design: The Role of Cytokine Network (eds Gregoriadis, G., McCormack, B. & Allison, A. C.) 181-185 (Plenum, New York, 1997).
29. Chapman, B. S., Thayer, R. M., Vincent, K. A. & Haigwood, N. L. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res. 19, 3979-3986 (1991).
30. Schultz, J., Pavlovic, J., Strack, B., Nawrath, M. & Moelling, K. Long-lasting anti-metastatic efficiency of IL-12-encoding plasmid DNA. Hum. Gene Ther. (in the press).